S. 3387 · 114th Congress
SAVINGS Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
CottonSponsorNo cosponsors.
Safely Advancing Valuable and Inexpensive New Generic Solutions Act or the SAVINGS Act
What it does: CRS summary · Introduced in Senate · Sep 22, 2016
Safely Advancing Valuable and Inexpensive New Generic Solutions Act or the SAVINGS Act
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to prioritize the review of certain generic drug applications and act on them within 150 days. This generic fast track review applies to applications for drugs: (1) that are not under patent or for which patents will expire soon, (2) for which there is no marketing exclusivity in effect, and (3) for which a generic has not recently been introduced to the market by more than one manufacturer.
The FDA must report on applications subject to generic fast track review and provide an annual accounting of how it has spent generic drug user fees.Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: SAVINGS Act
Also known as: Safely Advancing Valuable and Inexpensive New Generic Solutions Act
Latest action (Sep 22, 2016): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Sep 22, 2016
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.